The Experts below are selected from a list of 26307 Experts worldwide ranked by ideXlab platform
Michael Kuhl - One of the best experts on this subject based on the ideXlab platform.
-
the capz interacting protein rcsd1 is required for cardiogenesis downstream of wnt11a in xenopus laevis
Developmental Biology, 2017Co-Authors: Annemarie Hempel, Susanne J Kuhl, Melanie Rothe, Purushothama Rao Tata, Ioan Ovidiu Sirbu, Seppo Vainio, Michael KuhlAbstract:Wnt proteins are critical for embryonic cardiogenesis and cardiomyogenesis by regulating different intracellular signalling pathways. Whereas canonical Wnt/β-catenin signalling is required for mesoderm induction and proliferation of Cardiac progenitor cells, β-catenin independent, non-canonical Wnt signalling regulates Cardiac specification and terminal differentiation. Although the diverse Cardiac malformations associated with the loss of non-canonical Wnt11 in mice such as outflow tract (OFT) defects, reduced ventricular trabeculation, myofibrillar disorganization and reduced Cardiac Marker gene expression are well described, the underlying molecular mechanisms are still not completely understood. Here we aimed to further characterize Wnt11 mediated signal transduction during vertebrate cardiogenesis. Using Xenopus as a model system, we show by loss of function and corresponding rescue experiments that the non-canonical Wnt signalling mediator Rcsd1 is required downstream of Wnt11 for ventricular trabeculation, terminal differentiation of cardiomyocytes and Cardiac morphogenesis. We here place Rcsd1 downstream of Wnt11 during Cardiac development thereby providing a novel mechanism for how non-canonical Wnt signalling regulates vertebrate cardiogenesis.
-
comparative gene expression analysis and fate mapping studies suggest an early segregation of cardiogenic lineages in xenopus laevis
Developmental Biology, 2009Co-Authors: Susanne Gessert, Michael KuhlAbstract:Retrospective clonal analysis in mice suggested that the vertebrate heart develops from two sources of cells called first and second lineages, respectively. Cells of the first lineage enter the linear heart tube and initiate terminal differentiation earlier than cells of the second lineage. It is thought that both heart lineages arise from a common progenitor cell population prior to the Cardiac crescent stage (E7.5 of mouse development). The timing of segregation of different lineages as well as the molecular mechanisms underlying this process is not yet known. Furthermore, gene expression data for those lineages are very limited. Here we provide the first comparative study of Cardiac Marker gene expression during Xenopus laevis embryogenesis complemented by single cell RT-PCR analysis. In addition we provide fate mapping data of Cardiac progenitor cells at different stages of development. Our analysis indicates an early segregation of Cardiac lineages and a fairly complex heterogeneity of gene expression in the Cardiac progenitor cells. Furthermore, this study sets a reference for all further studies analyzing Cardiac development in X. laevis.
-
dm grasp alcam cd166 is required for Cardiac morphogenesis and maintenance of Cardiac identity in first heart field derived cells
Developmental Biology, 2008Co-Authors: Susanne Gessert, Daniel Maurus, Thomas Brade, Paul Walther, Petra Pandur, Michael KuhlAbstract:Vertebrate heart development requires specification of Cardiac precursor cells, migration of Cardiac progenitors as well as coordinated cell movements during looping and septation. DM-GRASP/ALCAM/CD166 is a member of the neuronal immunoglobulin domain superfamily of cell adhesion molecules and was recently suggested to be a target gene of non-canonical Wnt signalling. Loss of DM-GRASP function did not affect specification of Cardiac progenitor cells. Later during development, expression of Cardiac Marker genes in the first heart field of Xenopus laevis such as Tbx20 and TnIc was reduced, whereas expression of the second heart field Marker genes Isl-1 and BMP-4 was unaffected. Furthermore, loss of DM-GRASP function resulted in defective cell adhesion and Cardiac morphogenesis. Additionally, expression of DM-GRASP can rescue the phenotype that results from the loss of non-canonical Wnt11-R signalling suggesting that DM-GRASP and non-canonical Wnt signalling are functionally coupled during Cardiac development.
Stanely Mainzen P Prince - One of the best experts on this subject based on the ideXlab platform.
-
protective effect of caffeic acid on Cardiac Markers and lipid peroxide metabolism in cardiotoxic rats an in vivo and in vitro study
Metabolism-clinical and Experimental, 2010Co-Authors: Senthil K Kumaran, Stanely Mainzen P PrinceAbstract:Abstract Myocardial infarction affects a large population in the world. Lipid peroxide metabolism plays an important role in the pathology of myocardial infarction. This study aims to evaluate the preventive effect of caffeic acid on lipid peroxides, antioxidants, Cardiac Marker enzymes, and histopathological findings in isoproterenol (ISO)-induced myocardial-infarcted male Wistar rats. Myocardial infarction was induced in rats by subcutaneous injection of ISO (100 mg/kg) at an interval of 24 hours for 2 days. The ISO-induced rats showed significant increase in the levels of thiobarbituric acid reactive substances, lipid hydroperoxides in the heart, plasma uric acid, and serum Cardiac Marker enzymes, and significant decrease in the activities of heart superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, glutathione- S -transferase, and the levels of reduced glutathione, vitamin E, and vitamin C in the plasma and heart. Oral pretreatment with caffeic acid (15 mg/kg) daily for 10 days showed significant decrease in the levels of serum Cardiac Marker enzymes, heart lipid peroxidation products and plasma uric acid and significant increase in the levels of antioxidant system. Histopathology of myocardium also confirmed the protective effect of caffeic acid in myocardial-infarcted rats. In vitro study on total antioxidant activity (2,2'-azinobis-[3-ethylbenzothiazoline-6-sulfonic acid] + assay) confirmed the strong antioxidant action of caffeic acid. Thus, the present study revealed that caffeic acid ameliorates Cardiac damage in ISO-induced myocardial infarction by maintaining lipid peroxide metabolism due to its free radical scavenging and antioxidant effects. A diet containing caffeic acid may be beneficial to myocardial infarction.
-
cardioprotective effect of gallic acid on Cardiac troponin t Cardiac Marker enzymes lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in wistar rats
Chemico-Biological Interactions, 2009Co-Authors: Hansi D Priscilla, Stanely Mainzen P PrinceAbstract:Abstract Currently there has been an increased interest globally to identify antioxidant compounds that are pharmacologically potent and have low or no side effects for use in preventive medicine. This study was designed to evaluate the protective effect of gallic acid on Cardiac Marker enzymes, troponin-T, LDH-isoenzyme pattern, lipid peroxidation products and antioxidant status in isoproterenol (ISO)-induced myocardial infarction in male Wistar rats. Male albino Wistar rats were pretreated with gallic acid (15 mg/kg) daily for a period of 10 days. After the treatment period, ISO (100 mg/kg) was subcutaneously injected to rats at an interval of 24 h for 2 days. ISO-induced myocardial damage was indicated by increased activities of Marker enzymes such as creatine kinase, creatine kinase-MB, aspartate transaminase, alanine transaminase and lactate dehydrogenase in serum and the levels of troponin-T in the serum. Increased LDH-isoenzyme bands (LDH-1 and LDH-2) were also observed in serum of ISO-induced rats. In addition to these diagnostic Markers, the levels of lipid peroxidation products in plasma and the heart were significantly ( P P P
-
preventive effect of naringin on Cardiac Markers electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol induced myocardial infarction in wistar rats
Toxicology, 2007Co-Authors: M Rajadurai, Stanely Mainzen P PrinceAbstract:Diets rich in natural antioxidants are associated with reduced risk of heart diseases. This study was aimed to evaluate the preventive role of naringin on Cardiac troponin T (cTnT), lactate dehydrogenase (LDH)-isoenzyme, Cardiac Marker enzymes, electrocardiographic (ECG)-patterns and lysosomal enzymes in isoproterenol (ISO)-induced myocardial infarction (MI) in male Wistar rats. Rats subcutaneously injected with ISO (85mg/kg) at an interval of 24h for 2 days showed a significant increase in the levels of cTnT, intensity of the bands of LDH-isoenzyme (LDH1 and LDH2) and the activities of Cardiac Marker enzymes such as creatine kinase-MB (CK-MB), creatine kinase (CK), LDH, aspartate transaminase (AST) and alanine transaminase (ALT) in serum with subsequent decrease in the activities of CK, LDH, AST and ALT in the heart and alterations in ECG-patterns. The activities of lysosomal enzymes (beta-glucuronidase, beta-N-acetyl glucosaminidase, beta-galactosidase, cathepsin-B and cathepsin-D) were increased significantly in serum and the heart of ISO-induced rats, but the activities of beta-glucuronidase and cathepsin-D were decreased significantly in the lysosomal fraction of the heart. Pretreatment with naringin (10, 20 or 40mg/kg) daily for a period of 56 days positively altered the levels of cTnT, intensity of the bands of the LDH1 and LDH2-isoenzyme and the activities of Cardiac Marker enzymes, ECG-patterns and lysosomal hydrolases in ISO-induced rats. Thus, naringin possess cardioprotective effect in ISO-induced MI in rats.
Paul O. Collinson - One of the best experts on this subject based on the ideXlab platform.
-
how well do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction the Cardiac Marker guidelines uptake in europe study carmague
Clinical Chemistry, 2016Co-Authors: Paul O. Collinson, Robert H Christenson, Kari Pulkki, Janne Suvisaari, Marja P Van Dieijenvisser, Angelika Hammererlercher, Fred S. Apple, Christopher J Duff, Hannsjoerg Baum, Ana StavljenicrukavinaAbstract:BACKGROUND We undertook an assessment of current use of evidence-based guidelines for the use of Cardiac bioMarkers in Europe (EU) and North America (NA). METHODS In 2013-2014 a web-based questionnaire was distributed via NA and EU biochemical societies. Questions covered Cardiac bioMarkers measured, analytical methods used, decision thresholds, and use of decision-making protocols. Results were collated using a central database and analyzed using comparative and descriptive nonparametric statistics. RESULTS In EU, returns were obtained from 442 hospitals, 50% central or university hospitals, and 39% from local hospitals from 35 countries with 395/442 (89%) provided an acute service. In NA there were 91 responses (63.7% central or university hospitals, 19.8% community hospitals) with 76/91 (83.5%) providing an acute service. Cardiac troponin was the preferred Cardiac bioMarker in 99.5% (EU) and 98.7% (NA), and the first line Marker in 97.7% (EU) and 97.4% (NA). There were important differences in the choice of decision limits and their derivations. The origin of the information was also significantly different, with EU vs NA as follows: package insert, 61.9% vs 40%; publications, 17.1% vs 15.0%; local clinical or analytical validation choice, 21.0% vs 45.0%; P = 0.0003. CONCLUSIONS There are significant differences between EU and NA use of Cardiac bioMarkers. This probably relates to different availability of assays between EU and NA (such as high-sensitivity troponin assays) and different laboratory practices on assay introduction (greater local evaluation of assay performance occurred in NA).
-
evidence based laboratory medicine how well do laboratories follow recommendations and guidelines the Cardiac Marker guideline uptake in europe carmague study
Clinical Chemistry, 2012Co-Authors: Paul O. Collinson, Kari Pulkki, Janne Suvisaari, Jan Ravkilde, Hannsjörg Baum, Marja P Van Dieijenvisser, Angelika Hammererlercher, Ana Stavljenicrukavina, Päivi LaitinenAbstract:To the Editor: The original Cardiac Marker Guideline Uptake in Europe (CARMAGUE) study (1) surveyed laboratory practice against the then current clinical practice recommendations (2). The survey was repeated after the publication of the universal definition to see if newer recommendations were being followed (3, 4). An updated version of the questionnaire was implemented as a Web-based form linked to a database and was tested and validated. Data extraction to a spreadsheet allowed direct tabulation of the numbers of responses and combinations of responses for each question. A link to this form was sent via local representatives to a representative sample of laboratories in each country surveyed. The survey is available on the website http://www.carmague.fi/2/. Responses were obtained from 303 laboratories in 28 countries. The responders were from a full range of laboratories: 34% university hospital laboratories, 36% district hospitals, 25% central hospitals, and 5% primary care facilities. Ninety-five percent of the laboratories used troponin as the preferred Marker for routine diagnosis of suspected acute coronary syndromes. Fifty percent of the laboratories use troponin T, and 45% used troponin …
-
a pilot survey of the use and implementation of Cardiac Markers in acute coronary syndrome and heart failure across europe the Cardiac Marker guideline uptake in europe carmague study
Clinical Chemistry and Laboratory Medicine, 2009Co-Authors: Kari Pulkki, Paul O. Collinson, Janne Suvisaari, Jan Ravkilde, Hannsjörg Baum, Marja P Van Dieijenvisser, Angelika Hammererlercher, Ana Stavljenicrukavina, Päivi LaitinenAbstract:Background: Guidelines on preferred Cardiac Marker strategies for investigation of patients with acute coronary syndromes (ACS) are available from the laboratory medicine and cardiology communities. Therefore, implementation of these guidelines into daily clinical practice should be a joint effort of laboratory specialists and clinicians. This was investigated in this survey. Methods: A pilot study was performed sponsored by the European Federation of Clinical Chemistry and Laboratory Medicine. A link to an online questionnaire was e-mailed to 990 laboratories from eight European countries in May 2006. The requested information included tests performed, clinical protocol development, and reference limits. Results: We obtained a total of 220 responses. Out of these, 208 responses (95%) were from hospitals that provide 24-h admission of patients. The suggested turn-around-time ( 88% for Cardiac troponin T/I and for CK-MB mass. The majority of the laboratories derive their decision limits from kit inserts provided by the manufacturers. The results revealed a worrying fact that external quality assessments are not used in all testing. Conclusions: Our survey demonstrated that Cardiac troponin is the preferred bioMarker for the diagnosis of ACS. Half of the participants had written protocols, mostly as a result of collaboration between laboratorians and clinicians.
-
How Well Do Laboratories Follow Guidelines on Cardiac Markers? The Cardiac Marker Guideline Uptake in Europe Study
Clinical chemistry, 2008Co-Authors: Paul O. Collinson, Kari Pulkki, Janne Suvisaari, Jan Ravkilde, Ana Stavljenić-rukavina, Angelika Hammerer-lercher, Hannsjörg Baum, Marja P. Van Dieijen-visser, Päivi LaitinenAbstract:Evidence-based medicine is recognized as underlying good clinical practice. Similarly, evidence-based laboratory medicine should be used to guide and monitor laboratory testing. One area where laboratory testing has undergone a revolutionary change is in the diagnosis of acute coronary syndrome (ACS)1 , as underscored in the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) consensus document on the definition of and diagnostic approach of myocardial infarction in 2000, updated in 2007. Since the original reports, the measurement of cTnT and cTnI has been recommended in many guidelines, (1)(2) and they have formed a part of the redefinition of myocardial infarction (3). The Cardiac Marker Guideline Uptake in Europe study (CARMAGUE) was a pilot study to provide baseline data and validate a web-based audit tool to assess compliance of Cardiac Marker testing in current clinical practice. The study was sponsored by the European Federation of Clinical Chemistry and …
-
Surveys on the use of Cardiac Markers in the UK.
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2003Co-Authors: Man Tsang, Paul O. Collinson, Avril Owen, Julian H BarthAbstract:Background Troponin measurements are now central to the diagnosis of acute coronary syndromes and for the stratification of the severity of Cardiac disease. Some laboratories have quickly adopted the new testing strategies, which include troponin measurement for the diagnosis of acute myocardial infarction, while others are still developing appropriate protocols for Cardiac testing that they can support financially. However, it is not known how widespread is the adoption of these new strategies across the UK. Methods The National Audit Committee of the Association of Clinical Biochemists commissioned two surveys in 1999 and 2001 to assess the status of Cardiac Markers currently being offered by laboratories in the UK and how this service might develop in the future. Results The results show that many laboratories are continuously adapting and improving their Cardiac Marker testing in line with current recommendations for acute myocardial infarction. Although most laboratories are confident in the use of troponin measurement in the diagnosis of myocardial infarction, they are less confident in the use of biochemical Markers in assessing prognostic outcome in the other Cardiac conditions. Conclusions Finance, staffing and equipment constraints may offer significant impediments to troponin testing with a 1-h turnaround time. Ann Clin Biochem 2003; 40: 138‐142
Päivi Laitinen - One of the best experts on this subject based on the ideXlab platform.
-
evidence based laboratory medicine how well do laboratories follow recommendations and guidelines the Cardiac Marker guideline uptake in europe carmague study
Clinical Chemistry, 2012Co-Authors: Paul O. Collinson, Kari Pulkki, Janne Suvisaari, Jan Ravkilde, Hannsjörg Baum, Marja P Van Dieijenvisser, Angelika Hammererlercher, Ana Stavljenicrukavina, Päivi LaitinenAbstract:To the Editor: The original Cardiac Marker Guideline Uptake in Europe (CARMAGUE) study (1) surveyed laboratory practice against the then current clinical practice recommendations (2). The survey was repeated after the publication of the universal definition to see if newer recommendations were being followed (3, 4). An updated version of the questionnaire was implemented as a Web-based form linked to a database and was tested and validated. Data extraction to a spreadsheet allowed direct tabulation of the numbers of responses and combinations of responses for each question. A link to this form was sent via local representatives to a representative sample of laboratories in each country surveyed. The survey is available on the website http://www.carmague.fi/2/. Responses were obtained from 303 laboratories in 28 countries. The responders were from a full range of laboratories: 34% university hospital laboratories, 36% district hospitals, 25% central hospitals, and 5% primary care facilities. Ninety-five percent of the laboratories used troponin as the preferred Marker for routine diagnosis of suspected acute coronary syndromes. Fifty percent of the laboratories use troponin T, and 45% used troponin …
-
a pilot survey of the use and implementation of Cardiac Markers in acute coronary syndrome and heart failure across europe the Cardiac Marker guideline uptake in europe carmague study
Clinical Chemistry and Laboratory Medicine, 2009Co-Authors: Kari Pulkki, Paul O. Collinson, Janne Suvisaari, Jan Ravkilde, Hannsjörg Baum, Marja P Van Dieijenvisser, Angelika Hammererlercher, Ana Stavljenicrukavina, Päivi LaitinenAbstract:Background: Guidelines on preferred Cardiac Marker strategies for investigation of patients with acute coronary syndromes (ACS) are available from the laboratory medicine and cardiology communities. Therefore, implementation of these guidelines into daily clinical practice should be a joint effort of laboratory specialists and clinicians. This was investigated in this survey. Methods: A pilot study was performed sponsored by the European Federation of Clinical Chemistry and Laboratory Medicine. A link to an online questionnaire was e-mailed to 990 laboratories from eight European countries in May 2006. The requested information included tests performed, clinical protocol development, and reference limits. Results: We obtained a total of 220 responses. Out of these, 208 responses (95%) were from hospitals that provide 24-h admission of patients. The suggested turn-around-time ( 88% for Cardiac troponin T/I and for CK-MB mass. The majority of the laboratories derive their decision limits from kit inserts provided by the manufacturers. The results revealed a worrying fact that external quality assessments are not used in all testing. Conclusions: Our survey demonstrated that Cardiac troponin is the preferred bioMarker for the diagnosis of ACS. Half of the participants had written protocols, mostly as a result of collaboration between laboratorians and clinicians.
-
How Well Do Laboratories Follow Guidelines on Cardiac Markers? The Cardiac Marker Guideline Uptake in Europe Study
Clinical chemistry, 2008Co-Authors: Paul O. Collinson, Kari Pulkki, Janne Suvisaari, Jan Ravkilde, Ana Stavljenić-rukavina, Angelika Hammerer-lercher, Hannsjörg Baum, Marja P. Van Dieijen-visser, Päivi LaitinenAbstract:Evidence-based medicine is recognized as underlying good clinical practice. Similarly, evidence-based laboratory medicine should be used to guide and monitor laboratory testing. One area where laboratory testing has undergone a revolutionary change is in the diagnosis of acute coronary syndrome (ACS)1 , as underscored in the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) consensus document on the definition of and diagnostic approach of myocardial infarction in 2000, updated in 2007. Since the original reports, the measurement of cTnT and cTnI has been recommended in many guidelines, (1)(2) and they have formed a part of the redefinition of myocardial infarction (3). The Cardiac Marker Guideline Uptake in Europe study (CARMAGUE) was a pilot study to provide baseline data and validate a web-based audit tool to assess compliance of Cardiac Marker testing in current clinical practice. The study was sponsored by the European Federation of Clinical Chemistry and …
Susanne Gessert - One of the best experts on this subject based on the ideXlab platform.
-
comparative gene expression analysis and fate mapping studies suggest an early segregation of cardiogenic lineages in xenopus laevis
Developmental Biology, 2009Co-Authors: Susanne Gessert, Michael KuhlAbstract:Retrospective clonal analysis in mice suggested that the vertebrate heart develops from two sources of cells called first and second lineages, respectively. Cells of the first lineage enter the linear heart tube and initiate terminal differentiation earlier than cells of the second lineage. It is thought that both heart lineages arise from a common progenitor cell population prior to the Cardiac crescent stage (E7.5 of mouse development). The timing of segregation of different lineages as well as the molecular mechanisms underlying this process is not yet known. Furthermore, gene expression data for those lineages are very limited. Here we provide the first comparative study of Cardiac Marker gene expression during Xenopus laevis embryogenesis complemented by single cell RT-PCR analysis. In addition we provide fate mapping data of Cardiac progenitor cells at different stages of development. Our analysis indicates an early segregation of Cardiac lineages and a fairly complex heterogeneity of gene expression in the Cardiac progenitor cells. Furthermore, this study sets a reference for all further studies analyzing Cardiac development in X. laevis.
-
dm grasp alcam cd166 is required for Cardiac morphogenesis and maintenance of Cardiac identity in first heart field derived cells
Developmental Biology, 2008Co-Authors: Susanne Gessert, Daniel Maurus, Thomas Brade, Paul Walther, Petra Pandur, Michael KuhlAbstract:Vertebrate heart development requires specification of Cardiac precursor cells, migration of Cardiac progenitors as well as coordinated cell movements during looping and septation. DM-GRASP/ALCAM/CD166 is a member of the neuronal immunoglobulin domain superfamily of cell adhesion molecules and was recently suggested to be a target gene of non-canonical Wnt signalling. Loss of DM-GRASP function did not affect specification of Cardiac progenitor cells. Later during development, expression of Cardiac Marker genes in the first heart field of Xenopus laevis such as Tbx20 and TnIc was reduced, whereas expression of the second heart field Marker genes Isl-1 and BMP-4 was unaffected. Furthermore, loss of DM-GRASP function resulted in defective cell adhesion and Cardiac morphogenesis. Additionally, expression of DM-GRASP can rescue the phenotype that results from the loss of non-canonical Wnt11-R signalling suggesting that DM-GRASP and non-canonical Wnt signalling are functionally coupled during Cardiac development.